Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adapt Abi: Standard vs TDM-guided abiraterone dosing in metastatic castration-resistant prostate cancer
2025-524440-35-00Phase 4Authorised
- Sponsor
- Netherlands Cancer Institute
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of abiraterone in metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by Netherlands Cancer Institute. Primary endpoint: Radiographic progression-free survival. Planned start Apr 2026; status: authorised.
02
Drugs
abiraterone
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on 2025-524440-35-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524440-35-00.